Brenntag SE

2026 — Q2 results, upgraded 2026 EBITDA outlook and continued bolt‑on M&A

Brenntag reported strong Q2 2026 results with sales of EUR 4.3 billion (up approximately 11% year-over-year) and operating gross profit of EUR 1,146 million, representing a gross margin of 26.9%. The company raised its full-year operating EBITDA outlook for 2026 to EUR 1,350–1,450 million and announced completed and pipeline bolt-on deals including Woojin Trading (South Korea), Airedale (UK) and Chem Tech (US). [4][1][3]

After a weak 2024–2025 period, investor perception shifted toward cautious optimism as improving margins, cost-out delivery and early signs of demand recovery suggested resilience and potential for earnings reacceleration driven by pricing and portfolio upgrades. Management framed the story as disciplined growth plus margin restoration rather than aggressive top-line expansion. [4][3]

2026 (Q1) — Airedale acquisition closed; Q1 2026 interim statement

Brenntag closed the acquisition of Airedale Group (UK) and published its Q1 2026 interim statement showing lower sales versus the prior year but confirming EBITDA guidance range for 2026. Q1 2026 sales were EUR 3,662 million (down approximately 10.1% versus the prior-year quarter) and operating gross profit was approximately EUR 950 million. [1][8]

Investors viewed the Airedale and other bolt-ons as strategic, focused on shoring up Essentials and Specialties in core markets while the company navigated weak end-market demand. The market saw management continuing M&A even in subdued markets as a signal of confidence in long-term consolidation opportunities. [1][8]

2025 — Full‑year 2025 results: revenue decline, margin resilience, and selective acquisitions

Brenntag reported full-year 2025 sales of EUR 15.2 billion (down 3.7% versus 2024), with operating gross profit margin improving to 25.3%, operating EBITDA of approximately EUR 1.29 billion (down 8.6%) and operating EBITA of EUR 929 million (down 12.6%). Management disclosed approximately EUR 260 million of acquisitions signed or closed in 2025 including Chem Tech (US) and Airedale (UK). [11][3]

The narrative shifted from robust growth (pre-2022) to resilience and margin management. Investors saw Brenntag as executing portfolio strengthening and cost discipline while top-line was pressured by weak end markets and foreign exchange headwinds. Market sentiment was mixed, valuing the business for its scale but cautious on near-term earnings. [3][11]

2024 — Results below expectations; continued acquisitive posture (eight closed deals)

Brenntag published FY 2024 results showing sales of EUR 16.24 billion, operating gross profit of EUR 4.03 billion and operating EBITA of approximately EUR 1.10 billion. The company completed eight acquisitions in 2024 with total M&A spend reported around EUR 570 million for that year. Management acknowledged results "well below expectations." [12]

Investors perceived 2024 as a disappointment relative to prior momentum. Nevertheless, the active M&A cadence was interpreted as strategic market share and capability building. The story became one of a large distributor managing cyclical weakness while investing in specialty growth. [12]

2023 — Strategic expansion in Middle East and North America (Al‑Azzaz, Old World/OWI Chlor Alkali)

Brenntag completed several targeted acquisitions in 2023, including the entire business of Al‑Azzaz Chemicals Company (Saudi Arabia) and Old World Specialty Chemicals / Old World Logistics (OWI Chlor Alkali) in North America (completed in March and October 2023 respectively). These deals strengthened regional footprints and product portfolios in growth or core markets. [10][14]

The market viewed 2023 as a year of strategic consolidation and geographic expansion. Management emphasized long-term value creation through scale in attractive segments (caustic and industrial chemicals, regional distribution strength). Investor sentiment favored the strategy but remained watchful for integration execution and margin impacts amid evolving macro conditions. [10][14]

2022 — Strong earnings rebound (post‑pandemic / commodity cycle) — operating EBITDA increase

Brenntag recorded strong operating performance in 2022 driven by favourable pricing and volumes versus pandemic troughs and commodity dynamics. Operating EBITDA rose approximately 26.7% to just over EUR 1.81 billion for 2022. [15]

Investors framed Brenntag as a high-quality distributor and beneficiary of commodity and industrial cyclicality with pricing leverage. The company regained growth momentum and was discussed as a compounder benefiting from scale and pricing power, though some investors cautioned about cyclicality and later margin normalization risk. [15]